Diebold Nixdorf Statistics
Total Valuation
DBD has a market cap or net worth of $1.65 billion. The enterprise value is $2.49 billion.
| Market Cap | 1.65B |
| Enterprise Value | 2.49B |
Important Dates
The next estimated earnings date is Wednesday, February 12, 2025, before market open.
| Earnings Date | Feb 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DBD has 37.57 million shares outstanding. The number of shares has decreased by -49.87% in one year.
| Current Share Class | 37.57M |
| Shares Outstanding | 37.57M |
| Shares Change (YoY) | -49.87% |
| Shares Change (QoQ) | -0.27% |
| Owned by Insiders (%) | 0.56% |
| Owned by Institutions (%) | 75.20% |
| Float | 27.06M |
Valuation Ratios
The trailing PE ratio is 8,238.37 and the forward PE ratio is 9.95.
| PE Ratio | 8,238.37 |
| Forward PE | 9.95 |
| PS Ratio | 0.43 |
| Forward PS | 0.43 |
| PB Ratio | 1.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.97 |
| P/OCF Ratio | 14.25 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.14, with an EV/FCF ratio of 25.60.
| EV / Earnings | 12,428.37 |
| EV / Sales | 0.65 |
| EV / EBITDA | 6.14 |
| EV / EBIT | 9.16 |
| EV / FCF | 25.60 |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.02.
| Current Ratio | 1.45 |
| Quick Ratio | 0.71 |
| Debt / Equity | 1.02 |
| Debt / EBITDA | 2.72 |
| Debt / FCF | 11.33 |
| Interest Coverage | 1.61 |
Financial Efficiency
Return on equity (ROE) is 0.19% and return on invested capital (ROIC) is 7.48%.
| Return on Equity (ROE) | 0.19% |
| Return on Assets (ROA) | 4.28% |
| Return on Capital (ROIC) | 7.48% |
| Revenue Per Employee | $180,905 |
| Profits Per Employee | $10 |
| Employee Count | 21,000 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 4.38 |
Taxes
In the past 12 months, DBD has paid $57.30 million in taxes.
| Income Tax | 57.30M |
| Effective Tax Rate | 96.63% |
Stock Price Statistics
The stock price has increased by +57.71% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +57.71% |
| 50-Day Moving Average | 45.46 |
| 200-Day Moving Average | 40.95 |
| Relative Strength Index (RSI) | 41.81 |
| Average Volume (20 Days) | 151,968 |
Short Selling Information
The latest short interest is 343,038, so 0.91% of the outstanding shares have been sold short.
| Short Interest | 343,038 |
| Short Previous Month | 343,511 |
| Short % of Shares Out | 0.91% |
| Short % of Float | 1.27% |
| Short Ratio (days to cover) | 2.15 |
Income Statement
In the last 12 months, DBD had revenue of $3.80 billion and earned $200,000 in profits. Earnings per share was $0.00.
| Revenue | 3.80B |
| Gross Profit | 936.20M |
| Operating Income | 271.50M |
| Pretax Income | -390.00M |
| Net Income | 200,000 |
| EBITDA | 405.10M |
| EBIT | 271.50M |
| Earnings Per Share (EPS) | $0.00 |
Balance Sheet
The company has $262.40 million in cash and $1.10 billion in debt, giving a net cash position of -$838.00 million or -$22.31 per share.
| Cash & Cash Equivalents | 262.40M |
| Total Debt | 1.10B |
| Net Cash | -838.00M |
| Net Cash Per Share | -$22.31 |
| Equity (Book Value) | 1.08B |
| Book Value Per Share | 28.38 |
| Working Capital | 587.00M |
Cash Flow
In the last 12 months, operating cash flow was $115.60 million and capital expenditures -$18.50 million, giving a free cash flow of $97.10 million.
| Operating Cash Flow | 115.60M |
| Capital Expenditures | -18.50M |
| Free Cash Flow | 97.10M |
| FCF Per Share | $2.58 |
Margins
Gross margin is 24.64%, with operating and profit margins of 7.15% and 0.01%.
| Gross Margin | 24.64% |
| Operating Margin | 7.15% |
| Pretax Margin | 1.56% |
| Profit Margin | 0.01% |
| EBITDA Margin | 10.66% |
| EBIT Margin | 7.15% |
| FCF Margin | 2.56% |
Dividends & Yields
DBD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 49.87% |
| Shareholder Yield | 49.87% |
| Earnings Yield | 0.01% |
| FCF Yield | 5.89% |
Analyst Forecast
The average price target for DBD is $57.50, which is 31.10% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $57.50 |
| Price Target Difference | 31.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DBD has an Altman Z-Score of 1.65 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 6 |